JAK1 Q503*
|
Melanoma
|
JAK1 Q503*
|
Melanoma
|
nivolumab Resistant: C4 – Case Studies
|
nivolumab Resistant: C4 – Case Studies
|
JAK1 Q503*
|
Melanoma
|
JAK1 Q503*
|
Melanoma
|
pembrolizumab Resistant: C4 – Case Studies
|
pembrolizumab Resistant: C4 – Case Studies
|